Allogeneic cell therapy manufacturing: process development technologies and facility design options

References

• Global regenerative medicines market overview. Allied Market Research, 2016.
   Google Scholar
• Global biopharmaceuticals market. P&S Market Research, 2015.
   Google Scholar
• Annual data report on gene and cellular therapies and the regenerative medicine sector. Washington DC: 2016.
   Google Scholar
• Quarterly data report on gene and cell therpies and the regenerative medicine sector-Q3 2016. Washington: Alliance for Regenerative Medicine, 2016.
   Google Scholar
• Bullock MD, Silva AM, Kanlikilicer-Unaldi P, et al. Exosomal non-coding RNAs: diagnostic, prognostic and therapeutic applications in cancer. Non-Coding RNA. 2015;1:53–68.
   PubMedGoogle Scholar
• Heathman TR, Nienow AW, McCall MJ, et al. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen Med. 2015;10:49–64.
   PubMed Web of Science ®Google Scholar
• Abbasalizadeh S, Baharvand H. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol Adv. 2013;31:1600–1623.
   PubMed Web of Science ®Google Scholar
• Farid S. Cell therapy manufacturing strategies: impact on cost of goods, cost of development and commercialisation. Cell Culture Enginnering XV. 2016 May 8-13.
   Google Scholar
• Mazhari R, Hare JM. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nat Clin Pract Cardiovasc Med. 2007;4:S21–S6.
   PubMedGoogle Scholar
• Straathof K, Anoop P, Allwood Z, et al. Long-term outcome following cyclosporine-related neurotoxicity in paediatric allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2016; 52(1):159–162.
   PubMed Web of Science ®Google Scholar
• Griffin MD, Ryan AE, Alagesan S, et al. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol. 2013;91:40–51.
   PubMed Web of Science ®Google Scholar
• Charron D. Allogenicity & immunogenicity in regenerative stem cell therapy. Indian J Med Res. 2013;138:749.
   PubMed Web of Science ®Google Scholar
• LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. J Immunol. 2007;178:7503–7509.
   PubMed Web of Science ®Google Scholar
• Teng CW, Foley L, O’Neill P, et al. An analysis of supply chain strategies in the regenerative medicine industry—implications for future development. Int J Production Econ. 2014;149:211–225.
   Web of Science ®Google Scholar
• Simaria AS, Hassan S, Varadaraju H, et al. Allogeneic cell therapy bioprocess economics and optimization: single‐use cell expansion technologies. Biotechnol Bioeng. 2014;111:69–83.
   PubMed Web of Science ®Google Scholar
• Karantalis V, Schulman IH, Balkan W, et al. Allogeneic cell therapy a new paradigm in therapeutics. Circ Res. 2015;116:12–15.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619–1627.
   PubMed Web of Science ®Google Scholar
• Sabrina T, Schulman IH, Wayne B, et al. Allogeneic versus autologous source: comparative effects. In: Stem cell and gene therapy for cardiovascular disease. Academic Press (USA); 2015. p. 151–152.
   Google Scholar
• Joo S, Lim HJ, Jackson JD, et al. Myogenic-induced mesenchymal stem cells are capable of modulating the immune response by regulatory T cells. J Tissue Eng. 2014;5:11.
   Google Scholar
• Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res. 2015;2015:1–20.
   Web of Science ®Google Scholar
• Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32:252–260.
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13:392–402.
   PubMed Web of Science ®Google Scholar
• François M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012;20:187–195.
   PubMed Web of Science ®Google Scholar
• Kirsner RS, Marston WA, Snyder RJ, et al. Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2012;380:977–985.
   PubMed Web of Science ®Google Scholar
• Venugopal SS, Yan W, Frew JW, et al. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2013;69:898–908.e7.
   PubMed Web of Science ®Google Scholar
• Geissler EK, Hutchinson JA. Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients. Curr Opin Organ Transplant. 2013;18:408–415.
   PubMed Web of Science ®Google Scholar
• Niemann N, Sawitzki B. Treg therapy in transplantation: how and when will we do it? Curr Transplant Rep. 2015;2:233–241.
   Google Scholar
• Zhang J, Huang X, Wang H, et al. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res Ther. 2015;6:234.
   PubMed Web of Science ®Google Scholar
• Isakova IA, Lanclos C, Bruhn J, et al. Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in vivo. PloS One. 2014;9:e87238.
   PubMed Web of Science ®Google Scholar
• Griffin MD, Ryan AE, Alagesan S, et al. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far&quest. Immunol Cell Biol. 2013;91:40–51.
   PubMed Web of Science ®Google Scholar
• Mason C, Dunnill P. Assessing the value of autologous and allogeneic cells for regenerative medicine. Regen Med. 2009;4:835–853. Epub 2009/11/12.
   PubMed Web of Science ®Google Scholar
• Smith DM. Assessing commercial opportunities for autologous and allogeneic cell-based products. Regen Med. 2012;7:721–732. Epub 2012/09/08.
   PubMed Web of Science ®Google Scholar
• Van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521–3529.
   PubMed Web of Science ®Google Scholar
• Tögel F, Cohen A, Zhang P, et al. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev. 2009;18:475–486.
   PubMed Web of Science ®Google Scholar
• Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232–1240.
   PubMed Web of Science ®Google Scholar
• Jansen Of Lorkeers SJ, Eding JE, Vesterinen HM, et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res. 2015;116:80–86.
   PubMed Web of Science ®Google Scholar
• Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369–2379.
   PubMed Web of Science ®Google Scholar
• Cauldwell A. The commercialization of stem cells. Citeline. 2015;12.
   Google Scholar
• Valton J, Guyot V, Marechal A, et al. A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy. Mol Ther. 2015;23:1507–1518.
   PubMed Web of Science ®Google Scholar
• Aerts JG, Cornelissen R, van der Leest C, et al. Abstract CT229: autologous dendritic cells loaded with allogeneic tumor cell lysate in patients with mesothelioma: A phase I study. Cancer Res. 2015;75:CT229.
   Web of Science ®Google Scholar
• Dolstra H, Roeven MW, Spanholtz J, et al. A phase I study of allogeneic natural killer cell therapy generated from cord blood hematopoietic stem and progenitor cells in elderly acute myeloid leukemia patients. Blood. 2015;126:1357.
   PubMed Web of Science ®Google Scholar
• Lee D, Denman C, Rondon G, et al. Haploidentical NK cells infused prior to allogeneic stem cell transplant for myeloid malignancies: a phase I trial. Biol Blood Marrow Transplant: Journal American Society Blood Marrow Transplantation. 2016;22(7):1290-8.
   PubMed Web of Science ®Google Scholar
• Hourd P, Ginty P, Chandra A, et al. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy. 2014;16:1033–1047.
   PubMed Web of Science ®Google Scholar
• Hampson B, Rowley J, Venturi N. Manufacturing patient-specific cell therapy products. BioProcess Int. 2008;6.
   Google Scholar
• Westerdahl DE, Chang DH, Hamilton MA, et al. Allogeneic mesenchymal precursor cells (MPCs): an innovative approach to treating advanced heart failure. Expert Opin Biol Ther. 2016;16:1163–1169.
   PubMed Web of Science ®Google Scholar
• Dodson BP, Levine AD. Challenges in the translation and commercialization of cell therapies. BMC Biotechnol. 2015;15:70.
   PubMed Web of Science ®Google Scholar
• Harris DT. Stem cell banking for regenerative and personalized medicine. Biomedicines. 2014;2:50–79.
   PubMedGoogle Scholar
• Reinke S, Dienelt A, Blankenstein A, et al. Qualifying stem cell sources: how to overcome potential pitfalls in regenerative medicine? J Tissue Eng Regen Med. 2016;10:3–10.
   PubMed Web of Science ®Google Scholar
• Lee OK, Kuo TK, Chen W-M, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004;103:1669–1675.
   PubMed Web of Science ®Google Scholar
• Martins JP, Santos JM, Almeida JM, et al. Towards an advanced therapy medicinal product based on mesenchymal stromal cells isolated from the umbilical cord tissue: quality and safety data. Stem Cell Res Ther. 2014;5:1.
   PubMed Web of Science ®Google Scholar
• Abdulrazzak H, Moschidou D, Jones G, et al. Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues. J Royal Soc Interface. 2010;7:S689–S706.
   PubMed Web of Science ®Google Scholar
• RESEARCH ISFSC. Guidlines for stem cell reseach and clinical translation. 2016.
   Google Scholar
• Romanov YA, Darevskaya A, Merzlikina N, et al. Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities. Bull Exp Biol Med. 2005;140:138–143.
   PubMed Web of Science ®Google Scholar
• Perry BC, Zhou D, Wu X, et al. Collection, cryopreservation, and characterization of human dental pulp-derived mesenchymal stem cells for banking and clinical use. Tissue Engineering Part C: Methods. 2008;14:149–156.
   PubMed Web of Science ®Google Scholar
• Baghbaderani BA, Tian X, Cadet JS, et al. A newly defined and xeno-free culture medium supports every-other-day medium replacement in the generation and long-term cultivation of human pluripotent stem cells. PloS One. 2016;11:e0161229.
   PubMed Web of Science ®Google Scholar
• Chen G, Gulbranson DR, Hou Z, et al. Chemically defined conditions for human iPSC derivation and culture. Nat Methods. 2011;8:424–429.
   PubMed Web of Science ®Google Scholar
• Smith JR, Pfeifer K, Petry F, et al. Standardizing umbilical cord mesenchymal stromal cells for translation to clinical use: selection of GMP-compliant medium and a simplified isolation method. Stem Cells Int. 2016;2016:1-14.
   Web of Science ®Google Scholar
• Sabatino M, Hu J, Sommariva M, et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood. 2016;128:519–528. blood-2015-11-683847.
   PubMed Web of Science ®Google Scholar
• Chase LG, Yang S, Zachar V, et al. Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells. Stem Cells Transl Med. 2012;1:750–758.
   PubMed Web of Science ®Google Scholar
• Wu X, Kang H, Liu X, et al. Serum and xeno-free, chemically defined, no-plate-coating-based culture system for mesenchymal stromal cells from the umbilical cord. Cell Prolif. 2016;49:579–588.
   PubMed Web of Science ®Google Scholar
• De Sousa P, Downie J, Tye B, et al. Development and production of good manufacturing practice grade human embryonic stem cell lines as source material for clinical application. Stem Cell Res. 2016;17:379–390.
   PubMed Web of Science ®Google Scholar
• Gimble JM, Guilak F, Bunnell BA. Clinical and preclinical translation of cell-based therapies using adipose tissue-derived cells. Stem Cell Res Ther. 2010;1:1.
   Web of Science ®Google Scholar
• Zuliani T, Saiagh S, Knol A-C, et al. Fetal fibroblasts and keratinocytes with immunosuppressive properties for allogeneic cell-based wound therapy. PloS One. 2013;8:e70408.
   PubMed Web of Science ®Google Scholar
• Yi T, Kim SN, Lee HJ, et al. Manufacture of clinical-grade human clonal mesenchymal stem cell products from single colony forming unit-derived colonies based on the subfractionation culturing method. Tissue Eng Part C Methods. 2015;21:1251–1262.
   PubMed Web of Science ®Google Scholar
• Psaltis P, Paton S, See F, et al. Enrichment for STRO‐1 expression enhances the cardiovascular paracrine activity of human bone marrow‐derived mesenchymal cell populations. J Cell Physiol. 2010;223:530–540.
   PubMed Web of Science ®Google Scholar
• See F, Seki T, Psaltis PJ, et al. Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J Cell Mol Med. 2011;15:2117–2129.
   PubMed Web of Science ®Google Scholar
• Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397–405.
   PubMed Web of Science ®Google Scholar
• Eyquem J, Mansilla-Soto J, Odak A, et al. 274. one-step generation of universal CAR T cells. Mol Ther. 2016;24:1.
   PubMed Web of Science ®Google Scholar
• Cradick TJ. Cellular therapies: gene editing and next-gen CAR T cells. In: Rennert PD, editor. Novel Immunotherapeutic Approaches Treatment Cancer: Cham: Springer. 2016;203–247.
   Google Scholar
• Liu X, Zhang Y, Cheng C, et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 2016;27:154-7.
   PubMed Web of Science ®Google Scholar
• Riolobos L, Hirata RK, Turtle CJ, et al. HLA engineering of human pluripotent stem cells. Mol Ther. 2013;21:1232–1241.
   PubMed Web of Science ®Google Scholar
• Taylor CJ, Peacock S, Chaudhry AN, et al. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell. 2012;11:147–152.
   PubMed Web of Science ®Google Scholar
• Revazova ES, Turovets N, Kochetkova O, et al. HLA homozygous stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells. 2008;10:11–24.
   PubMedGoogle Scholar
• Chilima TDP, Bovy T. Designing the optimal manufacturing strategy for an adherent allogeneic cell therapy. Bioprocess Int. 2016;14:24–32.
   Google Scholar
• Lipsitz YY, Timmins NE, Zandstra PW. Quality cell therapy manufacturing by design. Nat Biotechnol. 2016;34:393–400.
   PubMed Web of Science ®Google Scholar
• Eaker S, Abraham E, Allickson J, et al. Bioreactors for cell therapies: current status and future advances. Cytotherapy. 2017;19:9–18.
   Web of Science ®Google Scholar
• Lawson T, Kehoe DE, Schnitzler AC, et al. Process development for expansion of human mesenchymal stromal cells in a 50L single-use stirred tank bioreactor. Biochem Eng J. 2016;120:49-62.
   Web of Science ®Google Scholar
• Schnitzler AC, Verma A, Kehoe DE, et al. Bioprocessing of human mesenchymal stem/stromal cells for therapeutic use: current technologies and challenges. Biochem Eng J. 2016;108:3–13.
   Web of Science ®Google Scholar
• Olmer R, Lange A, Selzer S, et al. Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue Engineering Part C: Methods. 2012;18:772–784.
   PubMed Web of Science ®Google Scholar
• Abbasalizadeh S, Larijani MR, Samadian A, et al. Bioprocess development for mass production of size-controlled human pluripotent stem cell aggregates in stirred suspension bioreactor. Tissue Engineering Part C: Methods. 2012;18:831–851.
   PubMed Web of Science ®Google Scholar
• Sart S, Tsai A-C, Li Y, et al. Three-dimensional aggregates of mesenchymal stem cells: cellular mechanisms, biological properties, and applications. Tissue Eng B: Rev. 2013;20:365–380.
   PubMed Web of Science ®Google Scholar
• Fonoudi H, Ansari H, Abbasalizadeh S, et al. A universal and robust integrated platform for the scalable production of human cardiomyocytes from pluripotent stem cells. Stem Cells Transl Med. 2015;4:1482–1494.
   PubMed Web of Science ®Google Scholar
• Sart S, Agathos SN. Large-scale expansion and differentiation of mesenchymal stem cells in microcarrier-based stirred bioreactors. Bioreactors Stem Cell Biology: Methods Protocols. 2016;1502:87–102.
   Google Scholar
• Badenes SM, Fernandes TG, Rodrigues CA, et al. Microcarrier-based platforms for in vitro expansion and differentiation of human pluripotent stem cells in bioreactor culture systems. J Biotechnol. 2016;234:71–82.
   PubMed Web of Science ®Google Scholar
• Rook M, Luther S, Murrell J, et al. Process optimization of human mesenchymal stem cell manufacturing at large scale. Cytotherapy. 2016;18:S152.
   Web of Science ®Google Scholar
• Mizukami A, Fernandes‐Platzgummer A, Carmelo JG, et al. Stirred tank bioreactor culture combined with serum-/xenogeneic-free culture medium enables an efficient expansion of umbilical cord-derived mesenchymal stem/stromal cells. Biotechnol J. 2016;11:1048–1059.
   PubMed Web of Science ®Google Scholar
• Kropp C, Kempf H, Halloin C, et al. Impact of feeding strategies on the scalable expansion of human pluripotent stem cells in single‐use stirred tank bioreactors. Stem Cells Transl Med. 2016;5:1289–1301.
   PubMed Web of Science ®Google Scholar
• Nemati S, Abbasalizadeh S, Baharvand H. Scalable expansion of human pluripotent stem cell-derived neural progenitors in stirred suspension bioreactor under xeno-free condition. Bioreactors Stem Cell Biology: Methods Protocols. 2016;1502:143–158.
   Google Scholar
• Rafiq QA, Coopman K, Nienow AW, et al. Systematic microcarrier screening and agitated culture conditions improves human mesenchymal stem cell yield in bioreactors. Biotechnol J. 2016;11:473–486.
   PubMed Web of Science ®Google Scholar
• Roh K-H, Nerem RM, Roy K. Biomanufacturing of therapeutic cells: state of the art, current challenges, and future perspectives. Annu Rev Chem Biomol Eng. 2016;7:455–478.
   PubMed Web of Science ®Google Scholar
• Wurm FM, de Jesus M. Manufacture of recombinant therapeutic proteins using Chinese hamster ovary cells in large-scale bioreactors. Biosimilars Monoclonal Antibodies: Practical Guide Manufacturing, Preclinical, Clinical Development. 2016:327–353.
   Google Scholar
• Kaiser SC, Kraume M, Eibl D, et al. Single-use bioreactors for animal and human cells. In: Al-Rubeai M, editor. Animal Cell Culture. Cham: Springer; 2015. p. 445–500.
   Google Scholar
• Correia C, Serra M, Espinha N, et al. Combining hypoxia and bioreactor hydrodynamics boosts induced pluripotent stem cell differentiation towards cardiomyocytes. Stem Rev Rep. 2014;10:786–801.
   PubMed Web of Science ®Google Scholar
• Tsai AC, Liu Y, Yuan X, et al. Aggregation kinetics of human mesenchymal stem cells under wave motion. Biotechnol J. 2017;12:26.
   Web of Science ®Google Scholar
• Vavrova K, Vrabcova P, Filipp D, et al. Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy. Med Oncol. 2016;33:136.
   PubMed Web of Science ®Google Scholar
• Alici E, inventor; Google Patents, assignee. Expansion of NK cells. USA patent US8877182 B2. 2014.
   Google Scholar
• Sutlu T, Stellan B, Gilljam M, et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy. 2010;12:1044–1055.
   PubMed Web of Science ®Google Scholar
• Wang X, Rivière I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Therapy-Oncolytics. 2016;3:16015.
   PubMed Web of Science ®Google Scholar
• Sousa MF, Silva MM, Giroux D, et al. Production of oncolytic adenovirus and human mesenchymal stem cells in a single-use, Vertical-Wheel bioreactor system: impact of bioreactor design on performance of microcarrier-based cell culture processes. Biotechnol Prog. 2015;31:1600–1612.
   PubMed Web of Science ®Google Scholar
• Lee B, Giroux D, Hashimura Y, et al. Scale-down model screening study of key process parameters for anchorage-dependent stem cells using vertical-wheel bioreactors. Cytotherapy. 2015;17:S30.
   Web of Science ®Google Scholar
• Chen AK-L, Chew YK, Tan HY, et al. Increasing efficiency of human mesenchymal stromal cell culture by optimization of microcarrier concentration and design of medium feed. Cytotherapy. 2015;17:163–173.
   PubMed Web of Science ®Google Scholar
• Bauwens C, Yin T, Dang S, et al. Development of a perfusion fed bioreactor for embryonic stem cell-derived cardiomyocyte generation: oxygen-mediated enhancement of cardiomyocyte output. Biotechnol Bioeng. 2005;90:452–461.
   PubMed Web of Science ®Google Scholar
• Simao D, Arez F, Terasso AP, et al. Perfusion stirred-tank bioreactors for 3D differentiation of human neural stem cells. Bioreactors Stem Cell Biology: Methods Protocols. 2016:129–142.
   Google Scholar
• Rowley J, Abraham E, Campbell A, et al. Meeting lot-size challenges of manufacturing adherent cells for therapy. BioProcess Int. 2012;10:7.
   Google Scholar
• Panchalingam KM, Jung S, Rosenberg L, et al. Bioprocessing strategies for the large-scale production of human mesenchymal stem cells: a review. Stem Cell Res Ther. 2015;6:225.
   PubMed Web of Science ®Google Scholar
• Dos Santos FF, Andrade PZ, Da Silva CL, et al. Bioreactor design for clinical-grade expansion of stem cells. Biotechnol J. 2013;8:644–654.
   PubMed Web of Science ®Google Scholar
• Lambrechts T, Papantoniou I, Viazzi S, et al. Evaluation of a monitored multiplate bioreactor for large-scale expansion of human periosteum derived stem cells for bone tissue engineering applications. Biochem Eng J. 2016;108:58–68.
   Web of Science ®Google Scholar
• Farid SS, Bovy T. Designing the optimal manufacturing strategy for an adherent allogeneic cell therapy. Bioprocess Int. 2016;14:24–32.
   Google Scholar
• Tsai A-C, Liu Y, Ma T. Expansion of human mesenchymal stem cells in fibrous bed bioreactor. Biochem Eng J. 2016;108:51–57.
   Web of Science ®Google Scholar
• Karnieli O. Cell therapy: early process development and optimization of the manufacturing process are critical to ensure viability of the product, quality, consistency and cost efficiency. J Commer Biotechnol. 2015:21.
   Google Scholar
• Wu FJ, Peshwa MV, Cerra FB, et al. Entrapment of hepatocyte spheroids in a hollow fiber bioreactor as a potential bioartificial liver. Tissue Eng. 1995;1:29–40.
   PubMedGoogle Scholar
• Nold P, Brendel C, Neubauer A, et al. Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. Biochem Biophys Res Commun. 2013;430:325–330.
   PubMed Web of Science ®Google Scholar
• Hanley PJ, Mei Z, Durett AG, et al. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. Cytotherapy. 2014;16:1048–1058.
   PubMed Web of Science ®Google Scholar
• Simón M. Bioreactor design for adherent cell culture. Bioprocess Int. 2015;13:1.
   Google Scholar
• Rayat AC, Chatel A, Hoare M, et al. Ultra scale-down approaches to enhance the creation of bioprocesses at scale: impacts of process shear stress and early recovery stages. Curr Opin Chem Eng. 2016;14:150–157.
   Web of Science ®Google Scholar
• Diogo MM, Da Silva CL, Cabral JM. Separation technologies for stem cell bioprocessing. In:Al-Rubeai M, Naciri, editors. Stem Cells and Cell Therapy. Dordrecht : Springer; 2014. p. 157–81.
   Google Scholar
• Kinney MA, Sargent CY, McDevitt TC. The multiparametric effects of hydrodynamic environments on stem cell culture. Tissue Eng B: Rev. 2011;17:249–262.
   PubMed Web of Science ®Google Scholar
• Cunha B, Peixoto C, Silva MM, et al. Filtration methodologies for the clarification and concentration of human mesenchymal stem cells. J Memb Sci. 2015;478:117–129.
   Web of Science ®Google Scholar
• Chisti Y. Hydrodynamic damage to animal cells. Crit Rev Biotechnol. 2001;21:67–110.
   PubMed Web of Science ®Google Scholar
• Ahsan T, Nerem RM. Fluid shear stress promotes an endothelial-like phenotype during the early differentiation of embryonic stem cells. Tissue Eng. 2010;16:3547–3553.
   Google Scholar
• Stolberg S, McCloskey KE. Can shear stress direct stem cell fate? Biotechnol Prog. 2009;25:10–19.
   PubMed Web of Science ®Google Scholar
• Sharma S, Raju R, Sui S, et al. Stem cell culture engineering–process scale up and beyond. Biotechnol J. 2011;6:1317–1329.
   PubMed Web of Science ®Google Scholar
• Brandenberger R, Burger S, Campbell A, et al. Cell therapy bioprocessing. BioProcess Int. 2011;3:30–36.
   Google Scholar
• Richardson D. Collection of stem cells using the UniFuge® single use centrifuge. Florida: Publisher; 2015.
   Google Scholar
• Nicholson P, Storm E. Single-use tangential flow filtration in bioprocessing. Bioprocess Int. 2011 January;15.
   Google Scholar
• Shenkman R, Gunzelmann D, Yang T, et al. Bioreactor perfusion via single-use centrifugation has fewer product quality implications than tangential flow filtration. In: Kiss R, Harcum S, Chalmers J, editors. Palm Springs USA: Publisher; 2016.
   Google Scholar
• Heinemann ML, Ilmer M, Silva LP, et al. Benchtop isolation and characterization of functional exosomes by sequential filtration. J Chromatogr. 2014;1371:125–135.
   PubMed Web of Science ®Google Scholar
• Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11:268–277.
   PubMed Web of Science ®Google Scholar
• Li K, Kong Y, Zhang M, et al. Differentiation of pluripotent stem cells for regenerative medicine. Biochem Biophys Res Commun. 2016;471:1–4.
   PubMed Web of Science ®Google Scholar
• González‐González M, Vázquez‐Villegas P, García‐Salinas C, et al. Current strategies and challenges for the purification of stem cells. J Chem Technol Biotechnol. 2012;87:2–10.
   Web of Science ®Google Scholar
• Grützkau A, Radbruch A. Small but mighty: how the MACS®-technology based on nanosized superparamagnetic particles has helped to analyze the immune system within the last 20 years. Cytometry Part A. 2010;77:643–647.
   PubMed Web of Science ®Google Scholar
• González-González M, Mayolo-Deloisa K, Rito-Palomares M. PEGylation, detection and chromatographic purification of site-specific PEGylated CD133-Biotin antibody in route to stem cell separation. J Chromatogr B. 2012;15:182–186.
   Web of Science ®Google Scholar
• Diogo MM, Da Silva CL, Cabral J. Separation technologies for stem cell bioprocessing. Biotechnol Bioeng. 2012;109:2699–2709.
   PubMed Web of Science ®Google Scholar
• Kolkundkar U, Gottipamula S, Majumdar A. Cell therapy manufacturing and quality control: current process and regulatory challenges. J Stem Cell Res Ther. 2014;260:75–82.
   Google Scholar
• Bravery CA, Carmen J, Fong T, et al. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy. 2013;15:9–19. e9.
   PubMed Web of Science ®Google Scholar
• Williams DJ, Archer R, Archibald P, et al. Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14–15 September 2015. Regen Med. 2016;11:483–492.
   PubMed Web of Science ®Google Scholar
• Lonza. TiGenix and Lonza Sign Agreement for the Manufacture of Stem Cell-based Treatment 2015 [cited 2/3/2017]. Available from: http://www.lonza.com/about-lonza/media-center/news/2015/150212-tigenix-e.aspx
   Google Scholar
• Lonza. Mesoblast and Lonza Establish Strategic Global Manufacturing Alliance 2011 [cited 2/3/2017]. Available from: http://www.lonza.com/about-lonza/media-center/news/2011/mesoblast-and-lonza-establish-strategic-global-manufacturing-alliance.aspx.
   Google Scholar
• Couto DS, Perez-Breva L, Cooney CL. Regenerative medicine: learning from past examples. Tissue Eng. 2012;18:2386–2393.
   Google Scholar
• Grant R, Curtis M, Brown M. Planning for commercial scale of cell therapy and regenerative medicine products, part 2: clinical efficacy, reimbursement, and needle-to-needle logistics. Bioprocess Int. 2015;13:30–38.
   Google Scholar
• French A, Buckler RL, Brindley DA. Commercialization of regenerative medicine: learning from spin-outs. 2013. New York: Mary Ann Liebert, Inc. 140 Huguenot Street , 3rd Floor New Rochelle, NY 10801 USA.
   Google Scholar